BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26567765)

  • 21. Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.
    Amato T; Abate F; Piccaluga P; Iacono M; Fallerini C; Renieri A; De Falco G; Ambrosio MR; Mourmouras V; Ogwang M; Calbi V; Rabadan R; Hummel M; Pileri S; Leoncini L; Bellan C
    Am J Clin Pathol; 2016 Jan; 145(1):116-27. PubMed ID: 26712879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
    Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
    Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
    Pohlen M; Gerth HU; Liersch R; Koschmieder S; Mesters RM; Kessler T; Appelmann I; Müller-Tidow C; Berdel WE
    Am J Hematol; 2011 Dec; 86(12):E61-4. PubMed ID: 21898532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term clinical outcome of children and adolescents with Burkitt's lymphoma treated with rituximab combined with modified NHL-BFM-90 regimen].
    Li YX; Yin QS; Ai H; Mi RH; Zhang LN; Li YF; Wei XD; Song YP
    Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(8):605-610. PubMed ID: 30818930
    [No Abstract]   [Full Text] [Related]  

  • 27. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic differences between paediatric and adult Burkitt lymphomas.
    Havelange V; Pepermans X; Ameye G; Théate I; Callet-Bauchu E; Barin C; Penther D; Lippert E; Michaux L; Mugneret F; Dastugue N; Raphaël M; Vikkula M; Poirel HA
    Br J Haematol; 2016 Apr; 173(1):137-44. PubMed ID: 26887776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.
    Gonzalez-Farre B; Ramis-Zaldivar JE; Salmeron-Villalobos J; Balagué O; Celis V; Verdu-Amoros J; Nadeu F; Sábado C; Ferrández A; Garrido M; García-Bragado F; de la Maya MD; Vagace JM; Panizo CM; Astigarraga I; Andrés M; Jaffe ES; Campo E; Salaverria I
    Haematologica; 2019 Sep; 104(9):1822-1829. PubMed ID: 30733272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases].
    Wang YC; DU WC; Yin CY; Gong X; Li YF
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):561-565. PubMed ID: 35644197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
    Rizzieri DA; Johnson JL; Byrd JC; Lozanski G; Blum KA; Powell BL; Shea TC; Nattam S; Hoke E; Cheson BD; Larson RA;
    Br J Haematol; 2014 Apr; 165(1):102-11. PubMed ID: 24428673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
    van Imhoff GW; van der Holt B; MacKenzie MA; Ossenkoppele GJ; Wijermans PW; Kramer MH; van 't Veer MB; Schouten HC; van Marwijk Kooy M; van Oers MH; Raemaekers JM; Sonneveld P; Meulendijks LA; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    Leukemia; 2005 Jun; 19(6):945-52. PubMed ID: 15800666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India.
    Srinivasan S; Roy Moulik N; Kc A; Narula G; Sankaran H; Prasad M; Dhamne C; Cheriyalinkal Parambil B; Shah S; Shet T; Sridhar E; Gujral S; Banavali S
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28682. PubMed ID: 32865865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
    Nelson M; Perkins SL; Dave BJ; Coccia PF; Bridge JA; Lyden ER; Heerema NA; Lones MA; Harrison L; Cairo MS; Sanger WG
    Br J Haematol; 2010 Feb; 148(4):600-10. PubMed ID: 19895612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
    Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
    Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.
    Miles RR; Arnold S; Cairo MS
    Br J Haematol; 2012 Mar; 156(6):730-43. PubMed ID: 22260323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.
    Zayac AS; Olszewski AJ
    Leuk Lymphoma; 2020 Aug; 61(8):1784-1796. PubMed ID: 32255708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
    Oriol A; Ribera JM; Esteve J; Sanz MA; Brunet S; Garcia-Boyero R; Fernández-Abellán P; Martí JM; Abella E; Sánchez-Delgado M; Peñarrubia MJ; Besalduch J; Moreno MJ; Borrego D; Feliu E; Ortega JJ;
    Haematologica; 2003 Apr; 88(4):445-53. PubMed ID: 12681972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
    Wästerlid T; Jonsson B; Hagberg H; Jerkeman M
    Leuk Lymphoma; 2011 Nov; 52(11):2090-6. PubMed ID: 21718134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.